Ipilimumab-induced toxicities and the gastroenterologist

Area of Science:

• Immunology
• Oncology
• Gastroenterology

Background:

• Ipilimumab improves survival in advanced melanoma by modulating the immune system.
• Immune-related adverse events (irAEs) are common and can be severe, affecting organs like the liver and colon.
• Gastroenterologists play a key role in managing ipilimumab-induced hepatitis and colitis.

Purpose of the Study:

• To review and discuss treatment paradigms for severe ipilimumab-induced irAEs, specifically hepatitis and colitis.
• To evaluate the efficacy of various immunosuppressive agents and dosing strategies.
• To provide guidance for managing irAEs unresponsive to standard treatments.

Main Methods:

• Case series of five patients with ipilimumab-induced hepatitis or colitis.
• Review of current literature and management algorithms for ipilimumab-induced irAEs.
• Discussion of treatment options including high-dose steroids, mycophenolate mofetil, infliximab, azathioprine, and calcineurin inhibitors.

Main Results:

• High-dose parenteral pulsed methylprednisolone successfully treated ipilimumab-induced hepatitis in three patients.
• One patient with ipilimumab-induced colitis resolved with high-dose corticosteroids alone.
• Another patient with colitis required infliximab infusion for resolution.

Conclusions:

• Standard treatment recommendations for ipilimumab-induced irAEs may require adjustment.
• High-dose steroids and additional immunosuppressive agents are crucial for managing severe, refractory cases.
• Further systematic study on dosing and duration of immunosuppressive therapy is needed.